Communiqués Q BioMed Inc.

Actions

QBIO

US74736N1054

Temps Différé OTC Markets Autres places de cotation 16:39:33 03/07/2024			Varia. 5j.	Varia. 1 janv.
0,0001 ^USD	+9 900,00%		0,00%	-75,00%

2023	Q BioMed Inc. annonce ses résultats pour le premier trimestre clos le 28 février 2023	CI
2023	Q BioMed Inc. annonce ses résultats pour l'exercice clos le 30 novembre 2022	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Q BioMed Inc. Provides Update to Shareholders	23/06/23	PR
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe	17/04/23	AQ
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe	14/04/23	PR
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office	13/02/23	AQ
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office	10/02/23	PR
Q BIOMED INC. : Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	18/11/22	AQ
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	03/11/22	AQ
Q BIOMED PROVIDES SHAREHOLDER UPDATE	11/10/22	PR
Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER	27/09/22	PR
Q BioMed Inc. Provides Update to Shareholders	29/07/22	PR
Q BioMed : Quarterly Report for Quarter Ending May 31, 2022 (Form 10-Q)	28/07/22	PU
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	28/07/22	AQ
Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer	26/07/22	PR
Q BIOMED INC. : Unregistered Sale of Equity Securities (form 8-K)	13/05/22	AQ
Q BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar Markets	06/05/22	PR
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	14/04/22	AQ
Q BioMed announces publication of research showing augmented efficacy of its drug candidate Uttroside-B against liver cancer	16/03/22	PR
Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market	07/03/22	PR
Q BIOMED INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	28/02/22	AQ
Q BioMed Outlines Strategic Direction for 2022	14/02/22	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Q BioMed Inc.

Actions

QBIO

US74736N1054

Communiqués

Filtres